(Sharecast News) - Shares of Zealand Pharma tumbled on Monday after the Danish pharmaceutical group said one in five patients dropped out of a trial of Boehringer Ingelheim's experimental survodutide obesity drug due to gastrointestinal side effects.
Zealand said the Phase III trial in people living with obesity showed targeted 34%...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE